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Investigation of polycystic ovarian syndrome: variation in 
practice and impact on the speed of diagnosis
Amar M. Kariaa,*, Christopher J. Duffb,c,*, Adrian Healdd,e,  
Ingrid Brittonf, Anthony A. Fryerb,c and Pensée Wua,g      
Objective Accurate diagnosis of polycystic ovarian 
syndrome (PCOS) enables clinical interventions/
cardiometabolic risk factor management. Diagnosis can 
take over 2 years and multiple clinician contacts. We 
examined patterns of PCOS-associated biochemical 
investigations following initial consultation prior to pelvic 
ultrasound scan (USS).
Methods We determined in 206 women (i) the range of 
different biochemical test panels used in the diagnosis of 
PCOS in primary/secondary care prior to USS relative to 
national guidance in the UK and (ii) the relation between 
testing patterns and time to USS to highlight potential 
delays introduced by inappropriate testing.
Results In these 206 women, 47 different test 
combinations were requested at initial venepuncture; 
only 7 (3%) had the test panel suggested in UK guidance 
(follicle-stimulating hormone/luteinizing hormone/
testosterone/sex hormone-binding globulin/prolactin). 
The number of tests performed prior to USS varied from 
one test to all seven tests. There was an inverse relation 
between the number of biochemistry tests requested at 
initial venepuncture episode and ‘time to scan’. Those 
who had <3 tests had a significantly longer time from 
first request to USS (median 70 days) than those with 
3–7 tests (median 40 days; P = 0.002). One venepuncture 
episode prior to USS was associated with shorter ‘time 
to scan’ (median 29 days) than those with 2–4 episodes 
(median 255 days; P < 0.001).
Conclusion There was no identifiable pattern to 
biochemical investigations requested as part of the 
initial diagnostic evaluation in women with suspected 
PCOS. We recommend standardization of the initial 
biochemical panel of analytes for PCOS workup, with 
incorporation into hospital/general practice ordering 
software systems. Cardiovasc Endocrinol Metab XXX: 
000–000 Copyright © 2021 The Author(s). Published by 
Wolters Kluwer Health, Inc.
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Introduction
Polycystic ovarian syndrome (PCOS) is thought to be the 
most common endocrine disorder in women of reproduc-
tive age worldwide, affecting 8–10% of this group, including 
women living in South Asia [1–4]. It has a heterogeneous 
clinical presentation, including menstrual disturbances, 
infertility, overweight/obesity and hirsutism. Women with 
PCOS are at a higher risk of developing type-2 diabetes 
and have increased cardiovascular risk factors as compared 
to age and weight-matched women without PCOS. [5]. 
Accurate diagnosis is important for early intervention to 
prevent future adverse health outcomes and to initiate 
appropriate treatment. However, a recent study showed 
that it can take over 2 years and for the women to see more 
than three different healthcare professionals before the 
accurate diagnosis of PCOS is made [6].
Currently, there is no international consensus regarding 
the diagnostic criteria and the prevalence rate estimates 
differ depending on the diagnostic criteria used [1]. 
The American Association of Clinical Endocrinologists, 
American College of Endocrinology, and Androgen 
Excess and PCOS Society have jointly published best 
practices for evaluating and treating PCOS [2,3]. These 
bodies still use the 1990 National Institutes of Health 
(NIH) criteria (no ovarian scan). In the UK, the Rotterdam 
criteria are applied with PCOS diagnosed when two out 
of the following three criteria are met: chronic anovula-
tion, polycystic ovaries (PCO), or clinical or biochemical 
evidence of hyperandrogenism [1].
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Although the laboratory investigation of PCOS and its 
associated symptoms is clearly important, there is uncer-
tainty among clinicians around which tests should be 
requested, and in what order, prior to ultrasound scan-
ning. The webpage of ‘Lab Tests Online UK’ lists a wide 
range of possible investigations that may be performed 
[7], but does not specify which ones are recommended in 
specific situations. In the UK, the National Institute for 
Health and Care Excellence (NICE) Clinical Knowledge 
Summaries also provide guidance for clinicians on which 
tests to perform [8], on the basis of the guidelines from 
the Royal College of Obstetricians and Gynecologists [9]. 
Our observations of clinical practice suggest that these 
are not always followed.
We previously showed that there is a wide disparity in the 
diagnostic investigations requested for PCOS between 
different general practices, with the practice also influ-
enced by the demographics of the population [10,11]. 
Furthermore, it is clear that the wider clinical community 
is often uncertain about which test to request.
The objective of this study was to determine (i) the range 
of different biochemical test panels used in the diagno-
sis of PCOS in primary or secondary care prior to ultra-
sound scanning relative to NICE guidance and (ii) the 
relation between testing patterns with time to ultrasound 
scan with a view to highlighting the potential delay intro-
duced by inappropriate testing.
Methods
In order to identify women who had been investigated 
for PCOS using pelvic ultrasound scan (USS), the radi-
ology database at a single referral center, the University 
Hospital of North Midlands, a large Acute Trust covering 
Staffordshire, UK, was searched over a 26-month period. 
The search terms were PCOS, PCOM, PCO, multicystic 
and infertility in either the clinical details or the results 
sections of radiology reports.
Data were then collected from the Laboratory 
Information and Management System on the clinical 
biochemistry investigations performed in these women 
during the 2 years prior to the date of their pelvic ultra-
sound imaging. These were tests frequently requested 
by a range of primary and secondary care clinicians for 
diagnostic purposes in PCOS, specifically: luteinizing 
hormone, follicle-stimulating hormone (FSH), estradiol, 
progesterone, prolactin, total testosterone and sex hor-
mone-binding globulin (SHBG). From this, we identified 
a cohort of 206 women who underwent pelvic USS and 
had at least one of these tests during this period. As a 
service evaluation project, this project was exempt from 
requiring ethical approval.
Statistical analyses were performed using Stata (Release 
14. StataCorp LLC, College Station, Texas, USA). 
Kaplan–Meier plots and Cox’s proportional hazards 
regression were used to examine time to scan event data.
Results
Assessment of the pattern of relevant biochemical tests 
(FSH, luteinizing hormone, estradiol, testosterone, pro-
lactin, SHBG and progesterone) requested by primary 
and secondary care clinicians showed that various combi-
nations (panels) of these biochemical investigations were 
requested at the initial consultation, such that 47 differ-
ent permutations were conducted as part of the diagnos-
tic evaluation (Table 1).
FSH was the most commonly requested test and was pres-
ent in 34/47 test panels (accounting for 179/206 requests). 
The top five most common panel of initial tests were: 
FSH, luteinizing hormone, testosterone and prolactin 
(15%, n = 30), FSH, luteinizing hormone and testosterone 
(14%, n = 29), FSH and luteinizing hormone (10%, n = 21), 
FSH, luteinizing hormone and prolactin (8%, n = 16), and 
FSH, luteinizing hormone, estradiol, progesterone, pro-
lactin and testosterone (6%, n = 13). Only seven women 
(3%) had the initial panel suggested in NICE guidance 
(panel 7: FSH, luteinizing hormone, testosterone, SHBG 
and prolactin), with a further three women having these 
plus other tests [two with added estradiol (panel 19), 
one with added estradiol and progesterone (panel 27)]. 
SHBG was the most commonly missed test, being pres-
ent in only 10 of the 47 panels (Table 1).
The number of tests performed prior to ultrasound scan-
ning varied from a single test to the full panel of seven 
tests (Table 1). Examining the data, there appeared to be 
an inverse relationship between the number of biochem-
istry tests requested at the initial venepuncture episode 
and ‘time to scan’. Those who had less than three tests 
had a significantly longer time from the first request to 
pelvic USS (median time 70 days) than those with three 
to seven tests (median time 40 days; P = 0.002; HR = 1.6; 
95% CI, 1.2–2.2; Fig. 1a).
We also showed that women had up to four venepuncture 
episodes in the 2 years prior to their pelvic USS: 159 with 
a single venepuncture, 36 had two, 9 had three and 2 had 
four venepuncture episodes. One venepuncture episode 
was associated with a significantly shorter ‘time to scan’ 
(median time 29 days) than those with more than one 
venepuncture episode (median time 255 days; P < 0.001; 
HR = 1.6; 95% CI, 2.3–4.6; Fig. 1b).
Discussion
Our study demonstrates the wide variation in the bio-
chemical investigations requested as part of the diag-
nostic evaluation for PCOS prior to the sonographic 
assessment of the ovarian morphology when pelvic USS is 
performed. This means that management of PCOS with 
such measures as dietary intervention and metformin 
may be delayed by months, with a knock-on effect in 
terms of cardiometabolic health and cardiometabolic risk 
management in the longer term.
Only 7% of cases had the initial panel of tests suggested 
in UK national guidance (FSH, luteinizing hormone, 
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testosterone, SHBG and prolactin). Furthermore, the 
number of tests performed prior to USS was linked to the 
time taken to arrange the USS scan; requests compris-
ing fewer than three tests were associated with a longer 
delay before pelvic USS was performed. Similarly, those 
cases that had only one venepuncture episode had a sig-
nificantly shorter ‘time to scan’ than those with more than 
two to four venepuncture episodes. Hence, our data illus-
trate the need for appropriate test requesting, with the 
availability of clear guidance for any clinician who might 
see such patients, in order to ensure timely follow-up 
investigations.
Previously, we showed a wide variation in patterns of 
investigations in PCO/PCOS in UK primary care prior to 
general practice-coded cases with a diagnosis of PCOS, 
where the recommended endocrine tests were not as fre-
quently requested as expected [11]. This is consistent 
with the findings of the current study on testing prior to 
ultrasound scanning, though this study included requests 
from both primary and secondary care, indicating that the 
challenge in appropriate requesting is more widespread 
than that in general practice. We are not aware of any 
other studies which have investigated such variability in 
testing in women being investigated for symptoms asso-
ciated with PCOS. We did not include measurement of 
lipid or glycaemic status as this has been covered in pre-
vious papers and are not currently part of the diagnostic 
criteria for PCOS.
The observation of 47 different permutations in testing 
panels suggests that clinicians are unclear on what tests 
to perform in women with symptoms associated with 
PCOS. This is particularly highlighted by the lack of 
requesting of SHBG when investigating PCOS, despite 
its recommendation in guidelines from the Royal College 
Table 1 Panels of tests performed prior to ultrasound scan for suspected PCOS
Test panel number FSH Luteinizing hormone Testosterone SHBG Prolactin Oestradiol Progesterone Total tests in panel Total requests for panel
1 X X X  X   4 30
2 X X X     3 29
3 X X      2 21
4 X X   X   3 16
5 X X X  X X X 6 13
6     X   1 8
7 X X X X X   5 7
8 X X X   X  4 6
9       X 1 6
10 X X X  X  X 5 5
11 X    X   2 5
12 X X X  X X  5 4
13 X X     X 3 4
14 X X X    X 4 3
15 X X    X  3 3
16 X X    X X 4 3
17 X  X  X   3 3
18 X  X     2 3
19 X X X X X X  6 2
20 X X X X    4 2
21 X X   X X  4 2
22 X X   X X X 5 2
23 X  X     2 2
24 X       1 2
25   X X    2 2
26   X     1 2
27 X X X X X X X 7 1
28 X X X X  X  5 1
29 X X X   X X 5 1
30 X X  X    3 1
31 X X  X  X  4 1
32 X X   X  X 4 1
33 X  X  X  X 4 1
34 X  X  X X  4 1
35 X  X   X  3 1
36 X   X    2 1
37 X      X 2 1
38 X     X  2 1
39  X X   X X 4 1
40  X X   X  3 1
41  X   X  X 3 1
42   X X  X  3 1
43   X  X X X 4 1
44   X  X X  3 1
45   X  X   2 1
46     X X X 3 1
47     X X  2 1
Total panels 34 26 27 10 22 22 16   
Panels containing the tests recommended in the guidance are shown in bold.
FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin.
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of Obstetricians and Gynaecologists, National Institute 
for Health and Care Excellence and other international 
guidance [2,3,11,12]. Indeed, SHBG was only included in 
19 (9.2%) out of the 206 requests. We do recognize, how-
ever, that some of the variations may reflect the different 
presenting signs and symptoms associated with PCOS. 
Symptoms such as infertility may well prompt testing of 
estradiol and progesterone. In these cases, testosterone 
and SHBG as tests more relevant in the presence of hir-
sutism/acne might not be seen as a first-line test, though 
the disparity between testosterone and SHBG requesting 
in our study suggests that investigation for other causes 
Fig. 1
Kaplan–Meier survival plots showing an association between time to ultrasound scan and (a) number of tests at initial venepuncture episode and 
(b) number of venepuncture episodes.
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is not the sole cause of the variation. Furthermore, we 
and others have described the link between a low SHBG 
and insulin resistance which is frequently a feature of 
PCOS [13].
We determined that laboratory testing is a factor linked 
to delay in diagnosis in women with PCOS. However, 
most requests were made in general practice, as a sig-
nificant minority (12.6%) were requested by secondary 
care clinicians. The varied and yet nonspecific signs and 
symptoms with which women with PCOS present make 
the selection of appropriate tests by nonspecialists chal-
lenging [12].
Our findings imply that there may be a benefit in stand-
ardizing the approach to the investigation of women 
with symptoms suggestive of PCOS across primary and 
secondary care. There have been numerous attempts to 
improve the appropriateness of laboratory requesting 
[14,15]. One such approach might be the generation of 
specific panels of tests, linked to PCOS and/or its associ-
ated symptoms (e.g. acne, amenorrhea, hirsutism, infer-
tility and hair loss), accessible to clinicians via electronic 
test ordering systems. Test request panels have the bene-
fit of improving standardization and/or reducing inappro-
priate testing [16], but studies indicate that these need 
to be managed carefully in order to prevent excessive 
over-ordering of tests [17]. An agreed panel of tests at a 
single venepuncture would seem a sensible option.
The strength of this study lies in the comprehensive 
evaluation of a defined population of women with known 
USS ovarian morphology and their biochemical inves-
tigations, as requested by the clinicians who saw them, 
prior to the scan. On the other hand, this study is also 
limited by this selected group where all women under-
went pelvic USS. As such, we do not have any data on 
women who were diagnosed with PCOS based on clin-
ical presentation and biochemical investigations without 
any sonographic evaluation. Another limitation is that we 
did not have detailed information about comorbidities, 
medications and the day of the menstrual cycle when the 
investigation was performed.
In summary, there was no identifiable pattern to the bio-
chemical investigations requested as part of the initial 
diagnostic evaluation in women with suspected PCOS. 
We recommend standardization of the initial biochemi-
cal panel of analytes for PCOS workup, with incorpora-
tion into hospital and general practice ordering software 
systems. This should improve efficiency and diagnostic 
yield and, above all, will be very helpful to the doctors 
and nurses who perform the evaluation of PCOS in the 
everyday clinical setting, so that treatment can be started 
in a timely manner.
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